Platelet resistance is best defined as a lack of the desired pharmacologic effect
|
|
- Percival Jeffrey Burns
- 6 years ago
- Views:
Transcription
1 2Chapter 1 Anti-Platelet Resistance Oral Antiplatelet Therapy Resistance: Definition, diagnosis, and clinical implications Saurabh Gupta, MD Peter J. Casterella, MD Executive Summary Platelet resistance is best defined as a lack of the desired pharmacologic effect of an antiplatelet medication when it is taken as directed. Antiplatelet therapy resistance is common, with approximately half of all patients having resistance to either aspirin, clopidogrel, or both. It also confers an increased risk of adverse outcomes associated with acute coronary syndromes and percutaneous coronary interventions. Optimal management for patients with platelet resistance has not yet been established. Standardized methods of platelet function testing and interpretation, as well as integration of point-of-service testing, may assist in adjusting antiplatelet therapy to improve outcomes in patients with platelet resistance. Likewise, newer pharmacologic agents may demonstrate better efficacy and a lower incidence of resistance compared to the current standard of care of aspirin and clopidogrel. 1
2 SIS 2007 Yearbook Introduction Antiplatelet therapy with aspirin (ASA) mg/ day offers protection against myocardial infarction (MI), stroke, and death. The mechanism of aspirin s antiplatelet action was first described in 1971 by British pharmacologist John Vane. In platelets, ASA irreversibly inhibits the enzyme cyclooxygenase-1 (COX-1), which in turns inhibits production of thromboxane A2, a facilitator of platelet aggregation (Figure 1). Significant benefit is evident among patients with acute coronary syndromes, such as unstable angina or acute MI, patients undergoing percutaneous coronary and peripheral intervention, and those with chronic ischemic vascular disease, or cerebrovascular disease. With regard to safety, efficacy, and cost effectiveness, ASA has demonstrated the best risk-benefit ratio of any available therapy for acute MI. Clopidogrel and ticlopidine are both thienopyridine agents with similar therapeutic effects, although clopidogrel has a better safety and side effect profile. Clopidogrel is a prodrug that undergoes activation by the cytochrome P450 3A4 system to become an irreversible inhibitor of the platelet P2Y12 receptor by blocking the binding of adenosine 5 -diphosphate (ADP). Blocking ADP leads to direct inhibition of the binding of fibrinogen to the glycoprotein IIb/ IIIa complex, thereby inhibiting platelet aggregation. Clopidogrel has demonstrated significant benefit across a wide spectrum of coronary artery disease clinical scenarios including ST elevation myocardial infarction (STEMI), non-stemi, and routine percutaneous coronary intervention (PCI). Ticlopidine, as mentioned, is similarly effective but associated with frequent side effects including rash and gastrointestinal upset, as well as the rare but potentially life-threatening occurrence of neutropenia. Still, it remains an alternative when clopidogrel therapy is not tolerated. Parenteral glycoprotein (GP) IIb/IIIa antagonists inhibit the final common pathway of platelet aggregation, the crossbridging of platelets secondary to Clopidogrel bisulfate, Ticlopidine HCI GP/IIb/IIIa (fibrinogen Receptor, IV agents) aspirin COX ADP ADP Activation Didyridamole Phosphodiesterase Collagen Thrombin TXA ADP = adenosine diphosphate; TXA2 = thromboxane A; COX = cyclooxygenase. Schafer AI. Am J Med, 1996, 101: fibrinogen binding to the activated GP IIb/IIIa receptor, resulting in near complete inhibition of platelet aggregation. Platelet Resistance: Definition, Incidence, Prevalence, and Outcomes Definition of Platelet Resistance Platelet resistance is best defined as a lack of the desired pharmacologic effect of an antiplatelet medication when it is taken as directed. However, the definition is complicated by the absence of standardized methods for platelet function assessment and the use of multiple assays and agonists. The occurrence of an ischemic clinical event while on antiplatelet therapy, although reflective of treatment failure, does not necessarily indicate that resistance is present. There are two methods of platelet aggregation testing. The first, light transmission platelet aggregometry (LTA), has been the gold standard of platelet function analysis for decades. However, this technology is tedious, time consuming, and not available in all hospitals. Furthermore, results of LTA are not immediately available, and thus cannot be used to guide acute therapies in the catheterization laboratory setting. The second, point-of-care platelet function assays, have become available more recently and are analogous to an activated clotting time (ACT) in that results are immediately available to guide therapy. Light transmission aggregometry and point-ofcare platelet function assays typically express results as percent aggregation. The assessment of platelet function after administration of platelet inhibitors may be expressed as residual platelet aggregation, or as level of platelet inhibition, which is the inverse of residual platelet aggregation. The most widely accepted definition of ASA resistance is 70% residual platelet aggregation with 10 μmol ADP stimulation or 20% residual platelet aggregation with 0.5mg/ml arachadonic acid stimulation (1). With clopidogrel, a less than 10% change in 5 μmol ADP-mediated platelet aggregation compared to baseline defines the presence of clopidogrel resistance (2). Platelet resistance does not appear to be an all or none phenomenon. Some patients demonstrate nearly complete resistance to aspirin, clopidogrel, or both agents, while others have a partial, but incomplete response of their platelets to these agents. While the optimal dose of aspirin has not been established, a consistent dose of clopidogrel is utilized for routine clinical use. It is unclear whether one size fits all dosing of clopidogrel is appropriate, and it has been postulated 2
3 Chapter 1 Anti-Platelet Resistance that some individuals may require a higher maintenance dose of clopidogrel to achieve the desired platelet inhibitory effect. Aspirin Resistance: Incidence and Outcomes The incidence of aspirin resistance varies from 5-60% of patients with cardiovascular disease depending upon the definition and assay used, as well as the population studied (1). The etiology of aspirin resistance is poorly understood and likely involves a combination of clinical, cellular, and genetic factors (Figure 2) (3). Ischemic stroke patients with aspirin resistance have an increased risk of future cardiovascular events, including stroke, MI, or vascular death (4). In a study of 151 patients undergoing non-urgent PCI, the incidence of aspirin resistance was 19.2%. Despite pretreatment with clopidogrel, those patients who were aspirin-resistant had a significantly higher rate of CK-MB and troponin I elevation post-procedure than those who were aspirin-sensitive (51.7% vs. 24.6%, p=0.006) (5). Interestingly, there was a significantly higher incidence of women in the aspirin-resistant group (44.8%) compared with the aspirin-sensitive group (19.7%) (p=0.007). CLINICAL FACTORS Non-absorption Interaction with NSAIDs Acute coronary syndrome Congestive heart failure Hyperglycemia Catecholamine surge CELLULAR FACTORS Insufficient suppression of COX-1 Over-expression of COX-2 mrna Erythrocyte induced platelet activation Increased norepinephrine Generation of 8-iso-PGF 2α Resolvins GENETIC FACTORS COX-1 GP IIb/IIIa receptor polymorphism Collagen receptor polymorphism vwf receptor polymorphism P2Y1 single nucleotide polymorphism ASPIRIN RESISTANCE Figure 2 Factors Contributing to Aspirin Resistance* *adapted from Bhatt DL. J Am Coll Cardiol 2004;43: Clopidogrel Resistance: Prevalence and Outcomes The prevalence of clopidogrel resistance varies from 4-30% of patients with coronary artery disease (CAD) depending upon the clinical scenario, test assay, and clopidogrel dose (2,6,7). A number of extrinsic and intrinsic factors have been hypothesized as operative in the etiology of clopidogrel resistance (Figure 3) (7). Marked inter-individual variability in the platelet inhibitory response from clopidogrel has been demonstrated (Figure 4) (8). Among patients undergoing PCI, those with high pretreatment platelet reactivity are the most likely to demonstrate post-treatment resistance to clopidogrel (2). The early risk of PCI is related to the level of platelet aggregation during the procedure. Baseline platelet aggregation was measured in 802 consecutive patients receiving a 600 mg loading dose of clopidogrel before elective coronary stenting. Nearly 40% of patients demonstrated suboptimal platelet inhibition. By quartiles of increasing platelet aggregation, the 30-day incidence of death, MI, and target lesion revascularization was 0.5% in the first quartile, 0.5% in the second, 3.1% in the third, and 3.5% in the fourth (p = 0.034) (9). Time from clopidogrel loading has a strong effect on the change in platelet aggregation, but even patients on chronic clopidogrel therapy who exhibit high ADP-induced platelet aggregation are at increased risk for post-procedural ischemic events (10). Clopidogrel resistance has been associated with adverse outcomes in a variety of clinical scenarios. Up to 25% of STEMI patients undergoing primary PCI are resistant to clopidogrel and have an increased risk of adverse cardiovascular events including stent thrombosis (11). A recent study evaluated responsiveness to clopidogrel in 804 consecutive patients receiving sirolimus- Extrinsic Factors Dose Drug-Drug Interactions (i.e. Lipitor) CYP3A4 Activity Variable Pro-Drug absorption Variable active metabolite clearance Intrinsic Factors P2Y12 receptor variability in numbers or affinity for drug Increased intrinsic ADP levels Up-regulation of other platelet activation pathways Figure 3 Potential Mechanisms of Clopidogrel Resistance* *adapted from Nguyen TA et al. J Am Coll Cardiol 2005;45:
4 SIS 2007 Yearbook Figure 4 Distribution of 5μmol of adenosine diphosphate (ADP)-induced residual platelet aggregation in 544 patients after receiving clopidogrel therapy* *from Serebruany VL et al. J Am Coll Cardiol 2005;45: or paclitaxel-eluting stents. All patients received aspirin (325 mg) and a loading dose of 600 mg of clopidogrel followed by a maintenance dose of 75 mg daily. 13% of patients were not responsive to clopidogrel. At 6 months, the incidence of stent thrombosis was 8.6% in nonresponders and 2.3% in responders (p<0.001). By multivariate analysis, nonresponsiveness to clopidogrel was a strong independent predictor of stent thrombosis (hazard ratio [HR] 3.08, 95% confidence interval [CI] 1.32 to 7.16, p=0.009) (12) Patients with unstable angina undergoing PCI demonstrate lower inhibition of platelet aggregation following clopidogrel loading compared to patients with stable angina (13). These findings suggest that patients presenting with acute coronary syndromes (ACS) are a subgroup of patients with an increased likelihood of clopidogrel resistance. Treatment Modification in Patients with Platelet Resistance Aspirin Resistance The optimal treatment of ASA resistance remains unclear. It has been theorized that an increased aspirin dose may overcome resistance in some patients, especially those who are partial responders. However, while some small in-vitro studies show that increasing the dose of aspirin may overcome biological resistance, several large trials have demonstrated no significant difference in clinical outcomes with varying doses of ASA (14). There is also in-vitro evidence suggesting that aspirin-resistant patients may benefit from clopidogrel due to their increased platelet sensitivity to ADP (7,15). Similarly, it has been proposed that the use of a loading dose of clopidogrel may prevent adverse events in aspirin-resistant patients undergoing PCI. However, Chen and colleagues demonstrated that aspirin-resistant patients pre-treated with 300 mg of clopidogrel prior to PCI still had a greater than two-fold increase in the incidence of CK-MB elevation following PCI (5). Additionally, Lev and colleagues reported that 47% of aspirin-resistant individuals demonstrated concurrent clopidogrel resistance as well (16). Thus, it seems unlikely that the use of clopidogrel in aspirin-resistant patients will be a suitable therapeutic option. 4
5 Chapter 1 Anti-Platelet Resistance Clopidogrel Resistance As with aspirin resistance, the optimal therapeutic adjustment in the setting of clopidogrel resistance has yet to be determined. Gurbel and colleagues demonstrated that following PCI, a 300 mg loading dose of clopidogrel, followed by 75 mg daily maintenance dose is associated with an incidence of resistance of 63% at 2 hours, 31% at 2 and 5 days, and 15% at 30 days. The declining incidence of resistance over time suggests that a higher loading and/or maintenance dose might overcome resistance in some individuals (2). In a subsequent study, Gurbel and colleagues demonstrated superior levels of platelet inhibition in the first 24 hours after PCI with a 600 mg vs. 300 mg loading dose of clopidogrel (17). However, further increases in clopidogrel loading have not been shown to be beneficial. Price and colleagues reported that a 900 mg dose of clopidogrel provided no benefit in terms of magnitude or time to maximal platelet inhibition compared with a 600 mg dose, but both are superior to a 300 mg dose (18). Use of a Glycoprotein IIb/IIIa Antagonist In the setting of PCI, a potential way to combat both aspirin and clopidogrel resistance is the use of a parenteral glycoprotein (GP) IIb/IIIa antagonist. Prior clinical studies of the GP IIb/IIIa inhibitor class showed significant reductions in major adverse cardiac events, leading to the widespread use of these agents with PCI in the late 1990s and early 2000s. GP IIb/IIIa use lessened with more recent studies such as REPLACE 2 (19) and ISAR REACT (20), which demonstrated that not all PCI patients require aggressive antiplatelet therapy. However, the ISAR REACT 2 trial showed that ACS patients benefit from the addition of a GP IIb/IIIa antagonist to a baseline therapy of aspirin, clopidogrel 600 mg loading dose, and intravenous heparin when undergoing PCI (21). This finding of a benefit with GP IIb/IIIa antagonists in higher risk ACS patients may be associated with the higher incidence of platelet resistance demonstrated in ACS patients. It seems plausible that a bona fide indication for the use of GP IIb/IIIa inhibitors may be the presence of platelet resistance, especially in the clinical scenario of ACS. The RESISTOR (Research Evaluation to Study Individuals who Show Thromboxane or P2Y12 Receptor Resistance) trial is currently evaluating the role of GP IIb/IIIa inhibitors in PCI in the setting of platelet resistance. In this study, elective PCI patients who demonstrate platelet resistance on pre-procedure platelet function testing are randomized to GP IIb/IIIa inhibitor therapy with eptifibatide vs. placebo. The primary endpoint is myonecrosis as assessed by cardiac biomarker elevations. Future Directions in the Management of Platelet Resistance Effectively dealing with and resolving the clinical challenges posed by platelet resistance hinges upon several critical issues including: 1. The need for standardized, convenient, and easily interpretable point-of-care platelet function assays. 2. Development of standardized terminology and nomenclature to define platelet resistance and to characterize platelet function response to inhibitory therapies. 3. Development of new pharmacologic therapeutic agents to address the shortcomings of aspirin and clopidogrel. Increased use of point-of-care platelet function assays may lead to better therapy. However, to integrate the results of such assays into patient management, it will be necessary to standardize features such as agonist type and strength used to test specific anti-platelet agents, in addition to nomenclature of reporting test results. The ideal platelet function test will use whole blood (no requirement for specimen preparation), will accurately assess platelet responsiveness even in the setting of baseline therapy with antiplatelet medications, and will provide results in 10 minutes or less. Measurement of responsiveness to antiplatelet therapy creates the potential for individualized therapy. Eventually, prospective, randomized clinical trials will determine if monitoring of platelet function response to therapy and subsequent adjustment of antiplatelet therapy translates into improved clinical outcomes. Newer pharmacologic agents may demonstrate better efficacy and a lower incidence of resistance compared to the current standard of care of aspirin and clopidogrel. Prasugrel is a third generation thienopyridine with greater potency, more rapid onset, more consistent platelet inhibition, and a lower incidence of resistance compared to clopidogrel (22). Prasugrel is currently under evaluation in the TRITON TIMI 38 study, which is comparing it to clopidogrel in the setting of PCI. Other novel agents such as cangrelor and AZD6140 are rapid, reversible P2Y12 inhibitors that are direct inhibitors as opposed to prodrugs. 5
6 SIS 2007 Yearbook Conclusion O ral antiplatelet therapy resistance is common and conveys an increased risk of adverse outcomes with ACS and PCI. Patients with platelet resistance may require higher doses of oral antiplatelet therapies or more potent antiplatelet therapies (i.e. GP IIb/IIIa antagonists) to optimize outcomes. Standardized methods of platelet function testing and interpretation, along with integration of point-of-service testing may assist in individualizing antiplatelet therapy to improve outcomes in patients with platelet resistance. The advancement of new agents with a more reliable pharmacologic effect and reduced incidence of resistance may further assist in combating the deleterious effects of antiplatelet therapy resistance. References 1. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88: Gurbel PA, Bliden KP, Hiatt BL, O Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107: Bhatt DL. Aspirin resistance: More than just a laboratory curiosity. J Am Coll Cardiol 2004;43: Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thrombosis Research 1993;71: Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43: Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89: Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005;45: Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45: Hochholzer W, Trenk D, Bestehorn H-P, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48: Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49: Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:
7 Chapter 1 Anti-Platelet Resistance 12. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49: Soffer D, Moussa I, Harjaim KJ, Boura JA, Dixon SR, Grines CL, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina? Catheterization and Cardiovascular Interventions 2003;59: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324: Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107: Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. J Am Coll Cardiol 2006;47: Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (clear platelets) study. Circulation 2005;111: Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a pointof-care assay in healthy volunteers. The American Journal of Cardiology 2006;98: Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein iib/iiia blockade compared with heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary intervention: Replace-2 randomized trial. JAMA 2003;289: Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350: Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The isar-react 2 randomized trial. JAMA 2006;295: Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:
Oral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationJournal of the American College of Cardiology Vol. 45, No. 9, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.030
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationNew insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
More informationNew Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses
October 23, 2006 Refer to: Joedy Isert Eli Lilly and Company 317-276-5592 (office) 317-997-8544 (cell) Jo-ann Straat Daiichi Sankyo (USA) 973-359-2602 (office) Shigemichi Kondo Daiichi Sankyo (Tokyo) 81-3-6225-1126
More informationDo We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationAntiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More informationIMMATURE PLATELETS CLINICAL USE
HAEMATOLOGY FEBRUARY 217 WHITE PAPER IMMATURE PLATELETS CLINICAL USE Identifying poor antiplatelet drug response and its risks early on Platelets are important cells for repairing endothelial lesions,
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationJournal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 19, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.058
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationJournal of the American College of Cardiology Vol. 48, No. 11, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 11, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.12.084
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationContemporary issues on clopidogrel therapy
Intern Emerg Med (2009) 4:201 211 DOI 10.1007/s11739-008-0220-5 IM - REVIEW Contemporary issues on clopidogrel therapy Giuseppe Patti Æ Germano Di Sciascio Received: 23 July 2008 / Accepted: 4 December
More informationPrasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationInterventional Cardiology
Clinical Investigations Interventional Cardiology Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationUpcoming Evidence and Practice of Optimal Antiplatelet Therapy in DES Era?
Upcoming Evidence and Practice of ptimal Antiplatelet Therapy in DES Era? Polymorphism in Metabolism of Clopidogrel and Its Clinical Implications and Management Alexandra Lansky MD Columbia University
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationEvaluation of Clopidogrel Resistance. in ischemic stroke patients.
ORIGINAL ARTICLE Evaluation of Clopidogrel Resistance in Ischemic Stroke Patients Takuya Fukuoka, Daisuke Furuya, Hidetaka Takeda, Tomohisa Dembo, Harumitu Nagoya, Yuji Kato, Ichiro Deguchi, Hajime Maruyama,
More informationJournal of the American College of Cardiology Vol. 48, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.06.049
More informationVariability in Platelet Responsiveness to Clopidogrel Among 544 Individuals
Journal of the American College of Cardiology Vol. 45, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.09.067
More informationPeri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.01.005 STATE-OF-THE-ART
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationLow-dose aspirin increases aspirin resistance in patients with coronary artery disease
The American Journal of Medicine (2005) 118, 723-727 CLINICAL RESEARCH STUDY AJM Theme Issue: CARDIOLOGY Low-dose aspirin increases aspirin resistance in patients with coronary artery disease Pui-Yin Lee,
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationThrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
More informationOlga Gorchakova a, Nicolas von Beckerath b, *, Meinrad Gawaz a, Adrienne Mocz b, Alexander Joost b, Albert Schömig a,b, Adnan Kastrati b.
European Heart Journal (24) 25, 1898 192 Clinical research Antiplatelet effects of a mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
More informationRandomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity
Journal of the American College of Cardiology Vol. 53, No. 13, 9 9 by the American College of Cardiology Foundation ISSN 735-97/9/$36. Published by Elsevier Inc. doi:.16/j.jacc.8.12.25 CLINICAL RESEARCH
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationInterventional Cardiology
Interventional Cardiology Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS)
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationClopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology?
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? Matthew J. Price MD, FACC Director, Cardiac Catheterization Laboratory Scripps
More informationReview Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes
Review Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes Tirtha Patel V *, Jigna Shah S and Patel CN Department of Clinical Pharmacy, Shri Sarvajanik Pharmacy College, Mehsana, Gujarat,
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationPlatelet function testing in cardiovascular diseases
Hematology, 2005; 10 Supplement 1: 132 /137 PLATELET DISORDERS Platelet function testing in cardiovascular diseases ALAN D. MICHELSON From the Center for Platelet Function Studies, Departments of Pediatrics,
More informationPrevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Patients with Coronary Artery Disease or Ischemic Cerebrovascular Disease
Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 39, no. 3, 2009 289 Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Patients with Coronary
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationThe Effects of Aspirin and Clopidogrel Response on Myonecrosis After Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 6, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.08.017 The Effects
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationEarly and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 51, No. 21, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.04.002
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationC.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial
Clopidogrel for the Reduction of Events During Observation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial From Steinhubl et al, JAMA 2002;228:2411-20
More informationStudy objectives. Study design. Patient population
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial Matthew J. Price, MD,
More informationWhat hematologists should know about VerifyNow
What hematologists should know about VerifyNow Hematology fellows conference 12/13/2013 Presenter: Christina Fitzmaurice, MD, MPH Discussant: Daniel Sabath, MD, PhD HMC consult patient 54 yo woman admitted
More informationThe ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) Study
Journal of the American College of Cardiology Vol. 52, No. 23, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.047
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationEffective platelet inhibition at the time of percutaneous
Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention Willibald Hochholzer, MD; Dietmar Trenk,
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationNew antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy
Cairo, Egypt 2010 New antiplatelets in NSTEMI Steen D. Kristensen, FESC Department of Cardiology Aarhus University Hospital Skejby Denmark Overview: dual anti-platelet oral therapy Aspirin Clopidogrel
More informationClopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens
Journal of the American College of Cardiology Vol. 51, No. 11, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.12.013
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationClopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationAntiplatelet Agents in Acute Coronary Syndromes, NSTE-ACS
Antiplatelet Agents in Acute Coronary Syndromes, NSTE-ACS Is There Still a Role for IV Antiplatelet Agents (Cangrelor, GPIIbIIIA inhibitors)? François Schiele, MD, PhD Department of Cardiology, University
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationand Ticagrelor Professor of Medicine (Cardiology), Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
Role of Genotyping and Point-of-Care of Testing in Clopidogrel, Prasugrel, and Ticagrelor Ron Waksman, MD Ron Waksman, MD Professor of Medicine (Cardiology), Georgetown University Associate Director, Division
More informationMeasurement of Antiplatelet Therapeutic Efficacy
Measurement of Antiplatelet Therapeutic Efficacy Bonnie H. Weiner MD MSEC MBA FSCAI FACC FAHA Professor of Medicine Director, Interventional Cardiology Research St Vincent Hospital Worcester MA Disclosure
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationCase presentation 1: Mr F. is a
CLINICIAN UPDATE Platelet Function Testing in Cardiovascular Diseases Alan D. Michelson, MD Case presentation 1: Mr F. is a 60-year-old man with unstable angina who takes aspirin, 81 mg/day. A platelet
More informationClinical Aspects of Platelet Inhibitors and Thrombus Formation Telly A. Meadows and Deepak L. Bhatt. doi: /01.RES
Clinical Aspects of Platelet Inhibitors and Thrombus Formation Telly A. Meadows and Deepak L. Bhatt Circ Res. 2007;100:1261-1275 doi: 10.1161/01.RES.0000264509.36234.51 Circulation Research is published
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationAntiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants
Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants S. Hinan Ahmed, MD Anti-platelet Therapy: Simple Answer Bare metal stent
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationAntiplatelet Therapy. Briain Mac Neill
Antiplatelet Therapy Briain Mac Neill Galway University Hospital & National University of Ireland Galway Milestones in ACS Management Anti-Thrombin Rx Heparin LMWH Bivalirudin Anti-Platelet Rx Aspirin
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More informationUse of Clopidogrel in the Reduction of Myocardial Damage During Percutaneous Coronary Intervention
University of Kentucky UKnowledge Gill Heart & Vascular Institute Faculty Publications Heart & Vascular 3-19-29 Use of Clopidogrel in the Reduction of Myocardial Damage During Percutaneous Coronary Intervention
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationPOCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine
POCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine Jackie Coleman, Ph.D. Director of Scientific Affairs Accumetrics, Inc. San Diego, CA Goals
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationΔοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης Αναπλ. Καθηγητής Καρδιολογίας Ιπποκράτειο ΓΝΑ Haematology Research Laboratory!! Platelets Small anucleate discoid cells Involved
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationCilostazol: Triple Benefits More is Better!
Cilostazol: Triple Benefits More is Better! Matthew J. Price, MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute,
More informationOptimizing Platelet P2Y 12 Inhibition for Patients Undergoing PCI
Cardiovascular Drug Reviews Vol. 25, No. 2, pp. 188 203 C 2007 The Authors Journal compilation C 2007 Blackwell Publishing Inc. Optimizing Platelet P2Y 12 Inhibition for Patients Undergoing PCI Steven
More informationIncreased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 49, No. 6, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.050
More informationTim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define
More informationΔοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Ομάδες Εργασίας Φεβρουάριος 2016 Ξανθοπούλου Ιωάννα Καρδιολόγος Επιμ Β ΠΓΝΠατρών Nothing to disclose Platelet function testing (PFT) is helpful in identifying
More information